CRDL Stock Chart & Stats
$2.00
>-$0.01(-0.42%)
At close: 4:00 PM EDT
$2.00
>-$0.01(-0.42%)
Day’s Range― - ―
52-Week Range$0.88 - $2.28
Previous Close$1.33
Volume288.13K
Average Volume (3M)701.45K
Market Cap
$250.42M
Enterprise Value$145.28
Total Cash (Recent Filing)$26.08M
Total Debt (Recent Filing)$107.00K
Price to Earnings (P/E)―
Beta1.51
Next Earnings
Nov 12, 2026EPS Estimate
-0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.34
Shares Outstanding116,822,670
10 Day Avg. Volume564,759
30 Day Avg. Volume701,452
Financial Highlights & Ratios
PEG Ratio0.14
Price to Book (P/B)6.37
Price to Sales (P/S)0.00
P/FCF Ratio-4.77
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$9.50Price Target Upside375.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.29
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageVery low debt limits interest and refinancing pressure, preserving financial flexibility while the company advances its clinical pipeline. This provides a stronger funding position than a similarly loss-making biotech carrying substantial leverage.
Loss StabilizationThe reduction in annual net loss indicates that deterioration is not accelerating at the reported period level. Although profitability remains distant, loss stabilization can help management control resource consumption while clinical development continues.
Focused Clinical PipelineA focused cardiovascular pipeline gives the company a defined therapeutic strategy rather than a broad, unfocused discovery portfolio. Success in these serious conditions could create meaningful partnering or commercialization opportunities, though approval remains unproven.
Bears Say
Pre-Revenue BusinessWith no meaningful product revenue, the company cannot currently fund operations through customers or recurring sales. Its future value therefore depends heavily on clinical progress, regulatory approval and eventual commercialization of unapproved candidates.
Persistent Cash BurnSustained negative operating and free cash flow means ongoing research and operations require external capital. Continued funding needs can dilute shareholders or constrain development if financing conditions weaken before clinical milestones are reached.
Eroding Capital BaseThe substantial decline in equity and total assets reflects cumulative losses and cash consumption. A shrinking capital base reduces financial resilience and leaves less internally funded capacity to absorb delays, trial costs or regulatory setbacks.
Cardiol Therapeutics News
CRDL FAQ
What was Cardiol Therapeutics’s price range in the past 12 months?
Cardiol Therapeutics lowest stock price was $0.88 and its highest was $2.27 in the past 12 months.
What is Cardiol Therapeutics’s market cap?
Cardiol Therapeutics’s market cap is $250.42M.
When is Cardiol Therapeutics’s upcoming earnings report date?
Cardiol Therapeutics’s upcoming earnings report date is Nov 12, 2026 which is in 76 days.
How were Cardiol Therapeutics’s earnings last quarter?
Cardiol Therapeutics released its earnings results on Aug 12, 2026. The company reported -$0.036 earnings per share for the quarter, beating the consensus estimate of -$0.07 by $0.034.
Is Cardiol Therapeutics overvalued?
According to Wall Street analysts Cardiol Therapeutics’s price is currently Undervalued.
Does Cardiol Therapeutics pay dividends?
Cardiol Therapeutics does not currently pay dividends.
What is Cardiol Therapeutics’s EPS estimate?
Cardiol Therapeutics’s EPS estimate is -0.05.
How many shares outstanding does Cardiol Therapeutics have?
Cardiol Therapeutics has 116,822,670 shares outstanding.
What happened to Cardiol Therapeutics’s price movement after its last earnings report?
Cardiol Therapeutics reported an EPS of -$0.036 in its last earnings report, beating expectations of -$0.07. Following the earnings report the stock price went up 12.5%.
Which hedge fund is a major shareholder of Cardiol Therapeutics?
Currently, no hedge funds are holding shares in CRDL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cardiol Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$9.50 (375.00% Upside)
$9.50 (375.00% Upside)
Crowd Wisdom
Negative
Last 7 Days ▲ 2.1%
Last 30 Days ▼ 3.5%
Last 30 Days ▼ 3.5%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-46.90%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
41.62%
Trailing 12-Months
Company Description
Cardiol Therapeutics
Cardiol Therapeutics Inc. operates as a clinical-stage life sciences company, primarily engaged in the discovery and advancement of treatments designed to combat fibrosis and inflammation within the context of cardiovascular diseases. Its flagship product, CardiolRx, is currently undergoing a significant Phase II/III international clinical trial. This extensive study is randomized, double-blind, and placebo-controlled, evaluating CardiolRx's efficacy and safety as a heart-protective therapy to mitigate cardiovascular and respiratory issues in individuals hospitalized with COVID-19. Concurrently, the trial also assesses CardiolRx's role in addressing acute myocarditis. Beyond this, the company is developing an injectable, subcutaneous formulation of CardiolRx, intended to target cardiac scarring and inflammation that contribute to the development and worsening of heart failure. Established in 2017, Cardiol Therapeutics Inc. is based in Oakville, Canada.
CRDL Stock 12 Month Forecast
Average Price Target
$9.50
▲(375.00% Upside)
Technical Analysis
Bausch Health Companies
―
Knight Therapeutics
―
Cipher Pharmaceuticals
―
Medicure
―
Medexus Pharmaceuticals Inc
―
Ownership Overview
2.24% Insiders
0.04% Mutual Funds
21.26% Other Institutional Investors
75.70% Public Companies and
Individual Investors